Human Cardiac Troponin ITC-Complex Recombinant – Research Use Only

Human Cardiac Troponin ITC-Complex Recombinant is a high-purity heterotrimeric complex consisting of cardiac troponin I, T, and C subunits, supplied as a 50 µg solution (Catalog #B2016344). This biotechnology-grade recombinant protein is an essential calibrator and research tool for developing and validating high-sensitivity cardiac troponin immunoassays, studying myocardial injury mechanisms, and investigating sarcomere function in cardiovascular research.

Scientific Overview

The cardiac troponin ITC complex is the regulatory protein complex of the cardiac sarcomere thin filament. It consists of three subunits: Troponin C (calcium-binding), Troponin I (inhibitory), and Troponin T (tropomyosin-binding). Upon myocardial injury, the complex is released into circulation, making cardiac troponin the gold-standard biomarker for diagnosing acute myocardial infarction and other cardiac injuries. Recombinant human troponin ITC complex serves as a critical reference material for assay development, calibration of high-sensitivity immunoassays, and mechanistic studies of sarcomere regulation and calcium signaling in cardiomyocytes.

This Human Cardiac Troponin ITC-Complex Recombinant is suitable for:

• Calibration and standardization of high-sensitivity cardiac troponin assays
• Research on myocardial injury biomarkers and diagnostic test development
• Studies of sarcomere function, calcium regulation, and contractility
• Investigation of troponin release mechanisms and post-translational modifications
• Development of reference materials for cardiovascular diagnostics

Usage & Handling Guidance

Store at -80 °C for long-term stability. Thaw on ice and keep cold during use. Avoid repeated freeze–thaw cycles by preparing single-use aliquots. Dilute in appropriate assay buffer (e.g., PBS with 0.1% BSA or manufacturer-specific diluent) immediately before use.

• Recommended applications: Immunoassay calibration, biomarker research, and sarcomere studies
• Working concentration: Optimize empirically for your specific assay (commonly used as calibrator at ng/mL to µg/mL range)
• Stability: Stable at -80 °C; minimize freeze–thaw cycles
• Handling: Use protease-free conditions; keep on ice during dilution and assay setup

What You Get

• 50 µg recombinant human cardiac Troponin ITC-complex as a solution
• Heterotrimeric complex containing cardiac troponin I, T, and C subunits
• High-purity biotechnology-grade material suitable for sensitive immunoassay development
• Essential reference standard for cardiac biomarker research
• For research use only (RUO)

Why Researchers Choose It

• Authentic recombinant human cardiac troponin ITC complex for accurate assay calibration
• Critical reference material for high-sensitivity cardiac troponin immunoassay development
• Useful for mechanistic studies of myocardial injury and sarcomere regulation
• High-purity formulation ensures low background and reproducible results
• Supports standardization and validation of cardiovascular diagnostic tests

Frequently Asked Questions (FAQ)

• What subunits are included in this complex?
  The ITC complex contains cardiac troponin I, troponin T, and troponin C.
• What is the primary application of this reagent?
  It is mainly used as a calibrator and reference material for high-sensitivity cardiac troponin immunoassays.
• How should I store the product?
  Store at -80 °C to maintain long-term stability. Avoid repeated freeze–thaw cycles.
• Is this suitable for assay development?
  Yes. It is specifically designed as a high-purity standard for cardiac troponin assay calibration and validation.
• Can this be used in cell-based studies?
  It is primarily intended as a biochemical standard; for functional sarcomere studies, additional optimization may be required.

---

References

• Rayani K, Seffernick J, Li AY, Davis JP, Spuches AM, Van Petegem F, Solaro RJ, Lindert S, Tibbits GF. Binding of calcium and magnesium to human cardiac troponin C. J Biol Chem. 2021 Jan-Jun;296:100350.
• Rehman A, Yousuf S, Maken GR, Naqvi SRA, Murtaza G, Ahmad A. Cardiac Troponin-I, A Biomarker for Predicting COVID-Induced Myocardial Damage Prognosis. J Coll Physicians Surg Pak. 2023 May;33(5):498-503.
• Vylegzhanina AV, Kogan AE, Katrukha IA, Koshkina EV, Bereznikova AV, Filatov VL, Bloshchitsyna MN, Bogomolova AP, Katrukha AG. Full-Size and Partially Truncated Cardiac Troponin Complexes in the Blood of Patients with Acute Myocardial Infarction. Clin Chem. 2019 Jul;65(7):882-892.
• Johnson RA, Fulcher LM, Vang K, Palmer CD, Grossoehme NE, Spuches AM. In depth, thermodynamic analysis of Ca(2+) binding to human cardiac troponin C: Extracting buffer-independent binding parameters. Biochim Biophys Acta Proteins Proteom. 2019 Apr;1867(4):359-366.
• Vylegzhanina AV, Kogan AE, Katrukha IA, Antipova OV, Kara AN, Bereznikova AV, Koshkina EV, Katrukha AG. Anti-Cardiac Troponin Autoantibodies Are Specific to the Conformational Epitopes Formed by Cardiac Troponin I and Troponin T in the Ternary Troponin Complex. Clin Chem. 2017 Jan;63(1):343-350.
• Oyama MA, Solter PF. Validation of an immunoassay for measurement of canine cardiac troponin-I. J Vet Cardiol. 2004 Nov;6(2):17-24.
• Nefedova VV, Kopylova GV, Shchepkin DV, Kochurova AM, Kechko OI, Borzova VA, Ryabkova NS, Katrukha IA, Mitkevich VA, Bershitsky SY, Levitsky DI, Matyushenko AM. Impact of Troponin in Cardiomyopathy Development Caused by Mutations in Tropomyosin. Int J Mol Sci. 2022 Dec 11;23(24):15723.
• Rayani K, Hantz ER, Haji-Ghassemi O, Li AY, Spuches AM, Van Petegem F, Solaro RJ, Lindert S, Tibbits GF. The effect of Mg(2+) on Ca(2+) binding to cardiac troponin C in hypertrophic cardiomyopathy associated TNNC1 variants. FEBS J. 2022 Dec;289(23):7446-7465.
• Stevens CM, Rayani K, Singh G, Lotfalisalmasi B, Tieleman DP, Tibbits GF. Changes in the dynamics of the cardiac troponin C molecule explain the effects of Ca(2+)-sensitizing mutations. J Biol Chem. 2017 Jul 14;292(28):11915-11926.
• Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J. 2009 Apr;73(4):602-7.